AbbVie
Stock Forecast, Prediction & Price Target
AbbVie (ABBV) stock Price Target by analysts
AbbVie (ABBV) stock Price Target by analysts
Average Price Target
$211.67
Potential upside: 2.40%
AbbVie price prediction
What is AbbVie stock analysts` prediction?
AbbVie stock forecast: Based on 5 Wall Street analysts` predicted price targets for AbbVie in the last 3 months, the avarage price target is $211.67, with a high forecast of $NaN. The average price target represents a 2.40% change from the last price of $206.7.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
AbbVie stock Price Target by analysts
Full breakdown of analysts given AbbVie price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Evan David Seigerman BMO Capital | 0% 0/2 | 10 months ago | $208 0.63% upside | $201.61 | StreetInsider | Previous targets (1) |
Evan David Seigerman BMO Capital | 0% 0/2 | 11 months ago | $228 10.30% upside | $201.5 | StreetInsider | Previous targets (1) |
Geoff Meacham Citigroup | 0% 0/1 | 11 months ago | $226 9.33% upside | $201.5 | TheFly | Previous targets (0) |
Charlie Yang Bank of America Securities | 0% 0/1 | 11 months ago | $210 1.59% upside | $201.5 | TheFly | Previous targets (0) |
Geoff Meacham Bank of America Securities | 0% 0/1 | 11 months ago | $195 -5.65% downside | $188.57 | StreetInsider | Previous targets (0) |
Courtney Breen Bernstein | 0% 0/1 | 11 months ago | $203 -1.78% downside | $190.46 | TheFly | Previous targets (0) |
Christopher Raymond Raymond James | 33.33% 1/3 | about 1 year ago | $209 1.11% upside | $197.35 | StreetInsider | Previous targets (2) |
Evan Seigerman BMO Capital | 0% 0/2 | about 1 year ago | $214 3.53% upside | $172.01 | TheFly | Previous targets (1) |
Christopher Raymond Raymond James | 33.33% 1/3 | about 1 year ago | $190 -8.07% downside | $171.36 | StreetInsider | Previous targets (2) |
Rajesh Kumar HSBC | 0% 0/1 | over 1 year ago | $185 -10.49% downside | $162.14 | StreetInsider | Previous targets (0) |
James Shin Deutsche Bank | 0% 0/1 | over 1 year ago | $175 -15.33% downside | $156.96 | StreetInsider | Previous targets (0) |
Louise Chen Cantor Fitzgerald | 0% 0/1 | over 1 year ago | $200 -3.23% downside | $164.35 | StreetInsider | Previous targets (0) |
Evan Seigerman BMO Capital | 0% 0/2 | over 1 year ago | $180 -12.91% downside | $158.58 | TheFly | Previous targets (1) |
Carter Gould Barclays | 66.67% 2/3 | over 1 year ago | $195 -5.65% downside | $179.79 | StreetInsider | Previous targets (2) |
Tim Lugo William Blair | 0% 0/1 | over 1 year ago | $190 -8.07% downside | $163.91 | StreetInsider | Previous targets (0) |
Christopher Raymond Raymond James | 33.33% 1/3 | almost 2 years ago | $170 -17.75% downside | $142.03 | Benzinga | Previous targets (2) |
Gary Nachman Raymond James | 100% 1/1 | almost 2 years ago | $177 -14.36% downside | $149.12 | Benzinga | Previous targets (0) |
Vamil Divan Guggenheim | 100% 1/1 | over 2 years ago | $171 -17.26% downside | $147.01 | Benzinga | Previous targets (0) |
Unknown BMO Capital | N/A | over 2 years ago | $167 -19.20% downside | $145.49 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $182 -11.94% downside | $163.44 | Benzinga | N/A |
Unknown Credit Suisse | N/A | almost 3 years ago | $170 -17.75% downside | $152.16 | Benzinga | N/A |
Unknown Leerink Partners | N/A | almost 3 years ago | $135 -34.68% downside | $142.72 | Benzinga | N/A |
Unknown Argus Research | N/A | about 3 years ago | $155 -25.01% downside | $137.91 | Benzinga | N/A |
Unknown Barclays | N/A | about 3 years ago | $160 -22.59% downside | $143.51 | Benzinga | N/A |
Terence Flynn Morgan Stanley | 0% 0/3 | about 3 years ago | $191 -7.59% downside | $152.15 | Pulse 2.0 | Previous targets (2) |
David Risinger Leerink Partners | 100% 1/1 | over 3 years ago | $140 -32.26% downside | $148.03 | Pulse 2.0 | Previous targets (0) |
Luisa Hector Berenberg Bank | 100% 1/1 | over 3 years ago | $135 -34.68% downside | $151.01 | Pulse 2.0 | Previous targets (0) |
Terence Flynn Morgan Stanley | 0% 0/3 | over 3 years ago | $188 -9.04% downside | $147.87 | Pulse 2.0 | Previous targets (2) |
Gary Nachman BMO Capital | 100% 2/2 | over 3 years ago | $174 -15.81% downside | $157.72 | TipRanks Contributor | Previous targets (1) |
Carter Gould Barclays | 66.67% 2/3 | over 3 years ago | $174 -15.81% downside | $162.31 | Pulse 2.0 | Previous targets (2) |
Terence Flynn Morgan Stanley | 0% 0/3 | over 3 years ago | $192 -7.10% downside | $168.91 | Pulse 2.0 | Previous targets (2) |
Navin Jacob UBS | 100% 1/1 | over 3 years ago | $147 -28.88% downside | $150.56 | Pulse 2.0 | Previous targets (0) |
Robyn Karnauskas Truist Financial | 100% 1/1 | over 3 years ago | $160 -22.59% downside | $144.03 | Pulse 2.0 | Previous targets (0) |
Vamil Divan Mizuho Securities | 100% 1/1 | over 3 years ago | $166 -19.68% downside | $140.65 | Pulse 2.0 | Previous targets (0) |
Chris Schott J.P. Morgan | 100% 1/1 | over 3 years ago | $180 -12.91% downside | $140.73 | TipRanks Contributor | Previous targets (0) |
Carter Gould Barclays | 66.67% 2/3 | over 3 years ago | $150 -27.42% downside | $140.73 | TheFly | Previous targets (2) |
Christopher Raymond Piper Sandler | 100% 1/1 | over 3 years ago | $160 -22.59% downside | $138.62 | TheFly | Previous targets (0) |
Joshua Schimmer Evercore ISI | 100% 1/1 | over 3 years ago | $133 -35.65% downside | $137 | TipRanks Contributor | Previous targets (0) |
Andrew Baum Citigroup | 100% 1/1 | over 3 years ago | $155 -25.01% downside | $137.92 | Pulse 2.0 | Previous targets (0) |
Gary Nachman BMO Capital | 100% 2/2 | over 3 years ago | $153 -25.97% downside | $136.78 | Pulse 2.0 | Previous targets (1) |
Steve Scala Cowen & Co. | 100% 1/1 | over 3 years ago | $150 -27.42% downside | $136.78 | TheFly | Previous targets (0) |
Aaron Gal Bernstein | 100% 1/1 | over 3 years ago | $155 -25.01% downside | $134.03 | StreetInsider | Previous targets (0) |
Mohit Bansal Wells Fargo | 100% 1/1 | almost 4 years ago | $165 -20.17% downside | $120.62 | TheStreet | Previous targets (0) |
Justin Smith Societe Generale | 100% 1/1 | almost 4 years ago | $172 -16.78% downside | $117.66 | TheStreet | Previous targets (0) |
David Toung Argus Research | 100% 1/1 | about 4 years ago | $140 -32.26% downside | $112.57 | TheFly | Previous targets (0) |
Daniel Busby RBC Capital | 100% 1/1 | about 4 years ago | $135 -34.68% downside | $112.9 | TipRanks | Previous targets (0) |
Tim Anderson Wolfe Research | 100% 1/1 | over 4 years ago | $127 -38.55% downside | $110.91 | StreetInsider | Previous targets (0) |
AbbVie Financial Estimates
AbbVie Revenue Estimates
AbbVie EBITDA Estimates
AbbVie Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $56.19B N/A | $58.05B 3.30% | $54.31B -6.43% | Avg: $58.19B Low: $56.58B High: $59.80B avg. 7.13% | Avg: $62.35B Low: $61.18B High: $63.79B avg. 7.15% | Avg: $66.33B Low: $65.08B High: $67.86B avg. 6.38% | Avg: $70.43B Low: $69.10B High: $72.05B avg. 6.17% |
Net Income
% change YoY
| $11.54B N/A | $11.83B 2.54% | $4.86B -58.91% | Avg: $11.43B Low: $6.18B High: $17.97B avg. 135.13% | Avg: $13.56B Low: $7.46B High: $19.70B avg. 18.64% | Avg: $26.05B Low: $25.41B High: $26.83B avg. 92.03% | Avg: $28.49B Low: $27.80B High: $29.34B avg. 9.37% |
EBITDA
% change YoY
| $26.44B N/A | $26.58B 0.52% | $17.30B -34.89% | Avg: $21.27B Low: $20.68B High: $21.86B avg. 22.92% | Avg: $22.79B Low: $22.36B High: $23.32B avg. 7.15% | Avg: $24.25B Low: $23.79B High: $24.81B avg. 6.38% | Avg: $25.75B Low: $25.26B High: $26.34B avg. 6.17% |
EPS
% change YoY
| $6.48 N/A | $6.65 2.62% | $2.73 -58.94% | Avg: $7.31 Low: $3.49 High: $10.14 avg. 167.77% | Avg: $8.41 Low: $4.21 High: $11.12 avg. 15.03% | Avg: $14.69 Low: $14.34 High: $15.13 avg. 74.74% | Avg: $16.07 Low: $15.68 High: $16.55 avg. 9.37% |
Operating Expenses
% change YoY
| $19.86B N/A | $21.82B 9.87% | $21.14B -3.11% | Avg: $13.73B Low: $13.35B High: $14.11B avg. -35.05% | Avg: $14.71B Low: $14.43B High: $15.05B avg. 7.15% | Avg: $15.65B Low: $15.36B High: $16.01B avg. 6.38% | Avg: $16.62B Low: $16.30B High: $17.00B avg. 6.17% |
FAQ
What is AbbVie stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 63.80% in 2025-2028.
We have gathered data from 14 analysts. Their low estimate is 6.18B, average is 11.43B and high is 17.97B.
What is AbbVie stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 6.71% in 2025-2028.
We have gathered data from 19 analysts. Their low revenue estimate is $56.58B, average is $58.19B and high is $59.80B.
What is AbbVie stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 66.73% in 2025-2028.
We have gathered data from 14 analysts. Their low earnings per share estimate is $3.49, average is $7.31 and high is $10.13.
What is the best performing analyst?
In the last twelve months 5 analysts have been covering AbbVie stock. The most successful analyst is Evan David Seigerman.